The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

The IMRAZ study found that patients treated with the Isa-VRD quadruplet who converted from MRD-negative to MRD-positive still had better outcomes than those on the VRD triplet. This suggests the four-drug regimen provides a deeper response or a lasting favorable impact on the tumor microenvironment beyond just achieving initial MRD negativity.

The clinical decision for newly diagnosed, transplant-ineligible myeloma patients has fundamentally shifted. Instead of determining who is eligible for a quadruplet regimen, the primary question for clinicians is now identifying the few patients who are not fit enough for this new standard of care.

In the maintenance setting, iberdomide isn't just a marginal improvement over the standard, lenalidomide. Cross-trial data suggests it more than doubles the rate of response improvement (70% vs. 30%) while surprisingly causing fewer side effects, such as gastrointestinal issues.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

New oral CELMoDs like mezigdemide show a surprising ability to make previously ineffective drugs, like bortezomib and carfilzomib, work again. This resensitization mechanism offers a powerful strategy to recycle older therapies, expanding options for heavily pretreated patients.

Based on findings from the DETERMINATION-1 and MIDAS trials, which questioned the overall survival benefit of early transplant, new strategies are emerging. The DETERMINATION-2 trial will use iberdomide-based therapy and defer transplant for standard-risk, MRD-negative patients, reserving it for higher-risk cases.

In newly diagnosed, transplant-ineligible myeloma, an iberdomide-based triplet (Iber-Dara-Dex) achieved 64% MRD negativity. This result is described as "astounding" because achieving MRD negativity is not even a realistic goal for comparable IMiD-based triplets like Dara-Len-Dex (the MAYA regimen). This sets a dramatically higher efficacy bar for frontline treatments.